GeneDx Q4 revenue up 64% YoY to $95.3M; adjusted net income $16.8M; FY2025 guidance $350-360M

GeneDx Holdings Corp.

2024-FY EPS reported -$1.94 revenue$305,450,000

Q4 revenues $95.3M (+64% YoY); exome/genome revenue $78.8M (+101% YoY).
Q4 adjusted gross margin 70% (vs 56% YoY); exome/genome margin >70%.
Q4 adjusted net income $16.8M (GAAP net income $5.4M); full year adjusted net income $6.7M.
FY2025 guidance: revenue $350M-$360M, exome/genome volume and revenue growth at least 30%.
Cash $142.2M at year-end; Q4 operating cash flow $12.4M including $6.8M appeal recovery.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.